Diagenode Launches Extensively Validated Epigenetic Antibodies for Broad Research Use

Share Article

Industry’s most highly validated antibodies as used by the BLUEPRINT Epigenome Consortium researchers are now broadly available for epigenetics researchers worldwide.

Liège, Belgium (PRWEB) November 04, 2013 -- Diagenode, Inc., a leading global provider of complete solutions for epigenetics research, recently launched its “Premium” line of antibodies for epigenetics applications such as chromatin immunoprecipitation (ChIP) and DNA methylation. These antibodies have been extensively validated for high sensitivity and specificity through a multi-step process including assessment through ELISA, dot blot, peptide arrays, Western blot, IF, CHIP-qPCR, and ChIP-seq. They were initially developed in a collaborative effort for the well-known BLUEPRINT Epigenome consortium and now have been released for widespread research use.

BLUEPRINT is a large-scale research project including 41 leading European universities, research institutes, and industry entrepreneurs who participate in one of the two high impact EU research initiatives. The BLUEPRINT consortium aims to uncover how genes are activated or repressed in healthy and diseased human cells by generating and studying at least 100 reference epigenomes. Quality standards for this project are set by the International Human Epigenome Consortium (IHEC).

Diagenode has been a long time supplier of epigenetic antibodies. Recently, the company introduced a three-tier antibody classification system in which antibodies are categorized by their degree of in-house validation. The highest tier of “Premium” antibodies receives its final status upon validation by epigenetics experts in the BLUEPRINT consortium. These antibodies have passed stringent bioinformatics tests from those defined by the NIH ENCODE project criteria and the Broad Institute reference data matching for ChIP-seq.

“Our partnership with the BLUEPRINT consortium enhances our partnership with the epigenetics community and our commitment to furthering epigenetics research,” said Didier Allaer, CEO of Diagenode. “We are pleased to be offering our Premium antibodies to enable the best possible ChIP-seq and DNA methylation data.”

More information on Diagenode’s antibody validation and the Premium antibodies that are utilized by the BLUEPRINT consortium can be found at http://www.diagenode.com.

About Diagenode, Inc.:
Diagenode is a leading provider of complete solutions for epigenetic research. The company has developed a comprehensive approach to gain new insights into epigenetic studies, offering innovative shearing and automation instruments, reagent kits, and high quality antibodies to streamline DNA methylation, ChIP, and ChIP-seq workflows. The company’s latest innovations include a unique, full automation system, ChIP-seq kits for only 10,000 cells, and the industry’s most validated antibodies. For more information about Diagenode, please visit the company’s website at http://www.diagenode.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Didier Allaer
Diagenode, Inc.
1 862 209 4680
Email >
Follow us on
Visit website